ALEXIS Biochemicals: GW1929

ALX-420-029

Revised 22-Feb-08

GW1929
SYNONYMS	N-(2-Benzoylphenyl)-L-tyrosine PPARγ Agonist (2S)-((2-Benzoylphenyl)amino-3-[4-[2-(methylpyridin-2-ylamino)ethoxy]phenyl)propionic acid
PRODUCT LINE	DNA Regulation / Transcription
PRODUCT CATEGORY	PPAR Agonists

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-420-029-M001		1 mg	80.00 USD
ALX-420-029-M005		5 mg	360.00 USD

Product Specification

FORMULA:	C₃₀H₂₉N₃O₄
MW:	495.6
PURITY:	≥97%
APPEARANCE:	Off-white to yellow crystalline solid.
SOLUBILITY:	Soluble in DMSO or methanol.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	+4°C
HANDLING:	Protect from light.

Product Description

Potent (<10nM) and subtype-selective (>1'000-fold) PPARγ agonist which does not contain a thiazolidinedione moiety. The glucose-lowering effect of GW1929 in rats is 100-fold more potent than that of troglitazone (Prod. No. ALX-270-355).

Product Specific Literature References

N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents: B.R. Henke, et al.; J. Med. Chem. 41, 5020 (1998) Abstract
Superoxide anion-dependent Raf/MEK/ERK activation by peroxisome proliferator activated receptor gamma agonists 15-deoxy-delta(12,14)-prostaglandin J(2), ciglitazone, and GW1929: W.C. Huang, et al.; Exp. Cell Res. 277, 192 (2002) Abstract
15-Deoxy-{delta}12,14-prostaglandin j2 inhibits interleukin-1{beta}-induced nuclear factor-{kappa}b in human amnion and myometrial cells: mechanisms and implications: T.M. Lindström & P.R. Bennett; J. Clin. Endocrinol. Metab. 90, 3534 (2005) Abstract; Full Text

another CS2 website

Online Product Ordering

Clipboard [0]

Your items will be kept only for the duration of your visit.